, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, Journal of Clinical Investigation, vol.105, issue.8, pp.15-24, 2000.
DOI : 10.1172/JCI8829
, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res, vol.60, issue.7, pp.1878-86, 2000.
, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J Clin Invest, vol.105, issue.8, pp.1045-1052, 2000.
, Metronomic chemotherapy: new rationale for new directions, Nat Rev Clin Oncol, vol.7, issue.8, p.20531380, 2010.
, Metronomics: towards personalized chemotherapy?, NatRrev Clin Oncol, vol.11, issue.7, pp.413-444, 2014.
, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors, Science, vol.313, issue.5794, pp.1785-1792, 2006.
, Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells, Cancer Res, vol.63, issue.15, pp.4342-4348, 2003.
, A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer, J Clin Oncol, vol.23, issue.5, pp.939-52, 2005.
, Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy, Cancer Res, vol.65, issue.16, pp.7045-51, 2005.
, Anti-bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy, Neoplasia, vol.16, issue.6, p.24957319, 2014.
, Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer, p.1579231, 2006.
, Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01, Trial J Cclinic Oncol, vol.2718, issue.9, pp.1368-74, 1200.
, Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome, Cancer Immunol Immunother, vol.61, issue.3, pp.353-62, 2012.
, A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer, Cancer Chemotherapy and Pharmacology, vol.366, issue.suppl 18, pp.229-267, 2014.
DOI : 10.1056/NEJMoa1111065
, Durable complete response of hepatocellular carcinoma after metronomic capecitabine, Tumori, vol.96, issue.8, p.463
, Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study, Oncologist, vol.18, issue.12, pp.1256-1263, 2013.
, Response assessment in metronomic chemotherapy: RECIST or PERCIST?, Indian J Nucl Med, vol.29, issue.2, p.3996775, 2014.
, Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience, Oncology, vol.21, issue.5, pp.249-60, 2012.
DOI : 10.1016/S0197-2456(00)00058-1
, Biomarkers and surrogate end points?the challenge of statistical validation, Nat Rev Clin Oncol, vol.7, issue.6, pp.309-326, 2010.
, A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors, J Pediatr Hematol Oncol, vol.28, issue.11, p.17114958, 2006.
, A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients, British Journal of Cancer, vol.92, issue.8, pp.1312-1321, 2008.
DOI : 10.1158/1078-0432.CCR-05-2255
, Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers, Angiogenesis, vol.15, issue.2, pp.275-86, 2012.
, VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide, British Journal of Cancer, vol.12, issue.4, p.3749570, 2013.
DOI : 10.1006/cyto.2000.0692
, Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer, Clinical Cancer Research, vol.15, issue.15, pp.4954-62, 2009.
DOI : 10.1158/1078-0432.CCR-08-3317
, CCR-08-3317 PMID, 19622584.
, First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study, Investigational New Drugs, vol.22, issue.6, pp.1725-1755, 2012.
DOI : 10.1111/j.1939-1676.2008.0179.x
, Has the time come for metronomics in low-income and middle-income countries?, Lancet Oncol, vol.14, issue.613, pp.239-287, 2013.
, Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India, Indian J Cancer, vol.48, issue.4, pp.391-397
, Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis, Indian J Cancer, vol.50, issue.2, pp.135-176
, Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01, J Pediatr Hematol Oncol, vol.33, issue.1, pp.31-35, 2011.
, Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02, Indian Journal of Cancer, vol.50, issue.3, pp.250-253, 2013.
DOI : 10.4103/0019-509X.118741
, Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma, Acta Neuropathol Commun, vol.1, issue.1, p.3893468, 2013.
, Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment, Oncotarget, vol.2, issue.10, pp.797-809, 2011.
DOI : 10.18632/oncotarget.343
, ??-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma, British Journal of Cancer, vol.15, issue.12, pp.2485-94, 2013.
DOI : 10.1056/NEJMoa0911123
, Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice, J Ped Surg, vol.48, issue.12, 2013.
, Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma, Oncotarget, vol.5, issue.1, pp.161-72, 2014.
, Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors Pediatr Blood Cancer, pp.511-518, 2012.
, Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study, Onkologie, vol.29, issue.7, pp.308-321, 2006.
, From tumor cell metabolism to tumor immune escape Intl, J Biochem Cell Biol, vol.451, pp.106-119, 2013.
, Chemical metabolic inhibitors for the treatment of blood-borne cancers, Anticancer Med Chem, vol.14, issue.2, pp.223-255, 2014.
, Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas, Cancer Treat Rev, vol.36, issue.10, pp.87-94, 2010.
, Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network BMC Cancer 9 pp 388 DOI: 10, p.2776604, 2009.
, Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-tomoderately differentiated neuroendocrine tumors: the XELBEVOCT study, BMC Cancer, vol.14, p.3996907, 2014.
, Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours, Endocrine Related Cancer, vol.26, issue.8, p.3255566, 2012.
DOI : 10.1200/JCO.2007.13.6374
, Adjuvant mitotane treatment for adrenocortical carcinoma, N Eng J Med, vol.356, issue.23, pp.2372-80, 2007.
, Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study, Endocrine Related Cancer, vol.17, issue.2, pp.445-53, 2010.
DOI : 10.1677/ERC-09-0281
, Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma, Eur J Endocrinol, vol.166, issue.3, pp.451-459, 2012.
, The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells, J Exp Med, vol.206, issue.3, pp.19273627-2664975, 2009.
, The Repurposing Drugs in, Oncology, vol.8, p.442, 2014.
, Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent Ecancermedicalscience 8 pp 443 PMID, pp.25075217-4096024, 2014.